KR20250007603A - B 및 t 림프구 감쇠제(btla) 조절제 및 이를 사용하는 방법 - Google Patents
B 및 t 림프구 감쇠제(btla) 조절제 및 이를 사용하는 방법 Download PDFInfo
- Publication number
- KR20250007603A KR20250007603A KR1020247039407A KR20247039407A KR20250007603A KR 20250007603 A KR20250007603 A KR 20250007603A KR 1020247039407 A KR1020247039407 A KR 1020247039407A KR 20247039407 A KR20247039407 A KR 20247039407A KR 20250007603 A KR20250007603 A KR 20250007603A
- Authority
- KR
- South Korea
- Prior art keywords
- btla
- sequence number
- seq
- variable region
- binding agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Transplantation (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263335623P | 2022-04-27 | 2022-04-27 | |
| US63/335,623 | 2022-04-27 | ||
| PCT/US2023/066258 WO2023212611A1 (en) | 2022-04-27 | 2023-04-26 | B and t lymphocyte attenuator (btla) modulators and method of using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250007603A true KR20250007603A (ko) | 2025-01-14 |
Family
ID=86558778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247039407A Pending KR20250007603A (ko) | 2022-04-27 | 2023-04-26 | B 및 t 림프구 감쇠제(btla) 조절제 및 이를 사용하는 방법 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250282872A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4514850A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025515337A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250007603A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023259623A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3256715A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL316496A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024013146A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023212611A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023004633A (es) * | 2020-10-23 | 2023-05-12 | Anaptysbio Inc | Moduladores del atenuador de linfocitos b y t (btla) y metodo de uso de los mismos. |
| WO2024243594A1 (en) * | 2023-05-25 | 2024-11-28 | Anaptysbio, Inc. | Btla agonist for mudulation of dendritic cells |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4828981A (en) | 1983-08-24 | 1989-05-09 | Synbiotics Corporation | Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| ATE159548T1 (de) | 1990-11-13 | 1997-11-15 | Immunex Corp | Bifunktionelle wählbare fusionsgene |
| AU6953394A (en) | 1993-05-21 | 1994-12-20 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
| US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
| JP5675109B2 (ja) | 2007-02-20 | 2015-02-25 | アナプティスバイオ インコーポレイティッド | ライブラリーの生成方法及びその使用 |
| CA2769473A1 (en) * | 2009-07-31 | 2011-02-03 | N.V. Organon | Fully human antibodies to btla |
| MX2023004633A (es) * | 2020-10-23 | 2023-05-12 | Anaptysbio Inc | Moduladores del atenuador de linfocitos b y t (btla) y metodo de uso de los mismos. |
-
2023
- 2023-04-26 AU AU2023259623A patent/AU2023259623A1/en active Pending
- 2023-04-26 US US18/859,958 patent/US20250282872A1/en active Pending
- 2023-04-26 WO PCT/US2023/066258 patent/WO2023212611A1/en not_active Ceased
- 2023-04-26 EP EP23726259.7A patent/EP4514850A1/en active Pending
- 2023-04-26 IL IL316496A patent/IL316496A/en unknown
- 2023-04-26 JP JP2024563361A patent/JP2025515337A/ja active Pending
- 2023-04-26 KR KR1020247039407A patent/KR20250007603A/ko active Pending
- 2023-04-26 CA CA3256715A patent/CA3256715A1/en active Pending
-
2024
- 2024-10-24 MX MX2024013146A patent/MX2024013146A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023212611A1 (en) | 2023-11-02 |
| JP2025515337A (ja) | 2025-05-14 |
| IL316496A (en) | 2024-12-01 |
| CA3256715A1 (en) | 2023-11-02 |
| US20250282872A1 (en) | 2025-09-11 |
| EP4514850A1 (en) | 2025-03-05 |
| MX2024013146A (es) | 2025-01-09 |
| AU2023259623A1 (en) | 2024-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7212098B2 (ja) | インターロイキン36受容体(il-36r)に対する抗体 | |
| JP7009543B2 (ja) | プログラム死-1(pd-1)に対する抗体 | |
| US20210095026A1 (en) | Antibodies Directed Against Lymphocyte Activation Gene 3 (LAG-3) | |
| US20220235132A1 (en) | Pd-1 agonist and method of using same | |
| US20250282872A1 (en) | B and t lymphocyte attenuator (btla) modulators and method of using same | |
| KR102805310B1 (ko) | Ccr9에 결합하는 치료용 결합 분자 | |
| US20230391872A1 (en) | B and t lymphocyte attenuator (btla) modulators and method of using same | |
| JP2025537224A (ja) | Cd122結合剤およびその使用方法 | |
| EA053216B1 (ru) | Модуляторы в- и т-лимфоцитарных аттенюаторов (btla) и способ их применения | |
| CN116685603A (zh) | B和t淋巴细胞衰减因子(btla)调节剂及其使用方法 | |
| HK40093375A (en) | B and t lymphocyte attenuator (btla) modulators and method of using same | |
| EA050223B1 (ru) | Агонист pd-1 и способ его применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20241126 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20250424 Comment text: Request for Examination of Application |